Impact of myc on anti-tumor immune responses in aggressive b cell non-hodgkin lymphomas: Consequences for cancer immunotherapy

A. Vera de Jonge*, Tuna Mutis, Margaretha G. M. Roemer, Blanca Scheijen, Martine E. D. Chamuleau

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review


Patients with MYC overexpressing high grade B cell lymphoma (HGBL) face significant dismal prognosis after treatment with standard immunochemotherapy regimens. Recent preclinical studies indicate that MYC not only contributes to tumorigenesis by its effects on cell proliferation and differentiation, but also plays an important role in promoting escape from anti-tumor immune responses. This is of specific interest, since reversing tumor immune inhibition with immunotherapy has shown promising results in the treatment of both solid tumors and hematological malignancies. In this review, we outline the current understanding of impaired immune responses in B cell lymphoid malignancies with MYC overexpression, with a particular emphasis on diffuse large B cell lymphoma. We also discuss clinical consequences of MYC overexpression in the treatment of HGBL with novel immunotherapeutic agents and potential future treatment strategies.
Original languageEnglish
Article number3052
Pages (from-to)1-21
Number of pages21
Issue number10
Publication statusPublished - 1 Oct 2020

Cite this